Skip to main content
. 2020 Jun 26;20:308. doi: 10.1186/s12872-020-01584-0

Table 1.

Baseline characteristics

Parameters Intracoronary prourokinase group (N = 25) Control group (N = 25) P value
Age, mean ± SD, years 59.48 ± 14.36 60.96 ± 12.56 0.700
Male, No. (%) 21 (80.8) 22 (88.0) 0.440
BMI, mean ± SD, kg/m2 25.69 ± 2.94 25.45 ± 2.89 0.769
Current smoker, No. (%) 12 (48.0) 13 (52.0) 0.777
Angina history, No. (%) 13 (52.0) 11 (44.0) 0.571
Hypertension, No. (%) 17 (47.2) 19 (52.8) 0.529
Diabetes mellitus, No. (%) 8 (32.0) 6 (24.0) 0.528
Dyslipidemia, No. (%) 8 (30.0) 5 (20.0) 0.333
Heart rate, mean ± SD, bpm 73.24 ± 14.22 77.40 ± 16.32 0.341
SBP, mean ± SD, mmHg 130.36 ± 24.31 131.72 ± 24.93 0.846
DBP, mean ± SD, mmHg 77.76 ± 15.56 81.92 ± 18.13 0.388
Killip grade, No. (%) 0.465
 I 10 (40.0) 14 (56.0)
 II 11 (44.0) 9 (36.0)
 III 4 (16.0) 2 (8.0)
Creatinine, mean ± SD, μmoI/L 85.32 ± 28.85 79.56 ± 16.23 0.389
GRF, mean ± SD, ml/min 91.17 ± 26.26 96.62 ± 20.49 0.418
RBC, mean ± SD, 10^9/L 4.54 ± 0.52 4.51 ± 0.55 0.845
NLR, mean ± SD 8.20 ± 5.53 8.19 ± 6.94 0.996
PLT, mean ± SD, 10^9/L 191.53 ± 91.73 220.92 ± 46.34 0.159
MPV, mean ± SD, fL 7.70 ± 2.70 8.43 ± 1.89 0.222
Medications prior to PCI, No.(%)
 Aspirin 25 (100.0) 25 (100.0) 1.000
 Ticagrelor 25 (100.0) 25 (100.0) 1.000
 Statins 25 (100.0) 25 (100.0) 1.000
 Heparin 25 (100.0) 25 (100.0) 1.000
 IIb/IIIa inhibitor 18 (72.0) 14 (56.0) 0.239
 Intravenous nitroglycerin 15 (60.0) 18 (72.0) 0.370
Medications at discharge, No.(%)
 ACEI 16 (64.0) 20 (80.0) 0.208
 B-blocker 14 (56.0) 18 (72.0) 0.239
 Statins 25 (100.0) 25 (100.0) 1.000
 DAPT 25 (100.0) 25 (100.0) 1.000

Differences between two groups were determined by Student’s t-test, Mann-Whitney U test, Chi-squared test or Fisher’s exact test, as appropriate. SD standard deviation, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, GRF glomerular filtration rate, RBC red blood count, NLR neutrophiltolymphocyte ratio, PLT platelet count, MPV mean platelet volume, PCI percutaneous coronary intervention, ACEI angiotension-converting enzyme, DAPT dual anti-platelet therapy